ClinicalTrials.gg
CompletedNCT05350072NEPTUNUS-1Updated Jul 7, 2026

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

A Phase 3 interventional study of VAY736 and Placebo in Sjogren Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 77 sites in 18 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.

Enrollment
6th of 14
275 · median 240
Started
2022
with 2 others
Phase 3
4 of 15
1 open now
Registered
10th of 15
by date

Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 10th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Sjogren's Syndrome by Novartis, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)

Read the detailed description

Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjogren's syndrome. The purpose of the study is to demonstrate the clinical efficacy, safety and tolerability of ianalumab (VAY736) administered subcutaneously (s.c.) monthly compared to placebo in patients with active Sjogren's syndrome.

03

Conditions studied

  • Sjogren Syndrome

Browse trials for

Keywords

  • Sjogren's syndrome
  • B-cell depleting
  • BAFF-R
  • VAY736
  • ianalumab
  • NEPTUNUS
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study
  • Women and men ≥ 18 years of age
  • Classification of Sjögren's syndrome according to the ACR/EULAR 2016 criteria
  • Time since diagnosis of Sjögren's of ≤ 7.5 years at screening
  • Positive anti-Ro/SSA antibody at screening

    • Patients negative for anti-Ro/SSA antibody are eligible, if they have a positive salivary gland confirmed by central expert review
    • Enrollment of anti-Ro/SSA-negative patients will be limited up to ≤10% of the study population
  • Screening ESSDAI score of ≥ 5 within the following 8 domains: constitutional, lymphadenopathy, glandular, articular, cutaneous, renal, hematological and biologic.
  • Stimulated whole salivary flow (sSF) rate of ≥ 0.05 mL/min at screening
  • Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study
  • Patients taking hydroxychloroquine (≤ 400 mg/day), methotrexate (≤ 25 mg/week) or azathioprine (≤ 150 mg/day) alone or in combination, are allowed to continue their medication, and must have been on a stable dose for at least 30 days prior to randomization.
  • Patients taking systemic have to be on a stable dose of ≤ 10 mg/day predniso(lo)ne or equivalent for at least 30 days before randomization.
  • Patients taking

    • disease-modifying antirheumatic drugs (DMARDs) other than specifically allowed by protocol
    • the following Traditional Chinese Medicines: Total glucoside of peony (TGP) or Tripterium glycosides (TG) must discontinue these medications at least 30 days prior to randomization, except for leflunomide, which has to be discontinued for 8 weeks prior to randomization unless a cholestyramine wash-out has been performed.

Exclusion criteria

Exclusion Criteria:

  • Presence of another rheumatic disease that is active and constitutes the principal illness
  • Use of other drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer3. Prior treatment with ianalumab
  • Prior use of a B-cell depleting therapy other than ianalumab within 36 weeks prior to randomization or as long as B-cell count is less than the lower limit of normal or baseline value prior to receipt of previous B cell-depleting therapy (whichever is lower)
  • Prior treatment with any of the following:

    1. Within 24 weeks prior to randomization: iscalimab (anti CD-40 mAb), belimumab , abatacept, anti-tumor necrosis factor alpha biologic agents, immunoglobulins plasmapheresis;
    2. Within 12 weeks prior to randomization: i.v. or oral cyclophosphamide and mycophenolate mofetil, i.v. or oral cyclosporine A or any other (e.g., JAK inhibitors or other kinase inhibitors) unless explicitly allowed by protocol
  • Use of (predniso(lo)ne or equivalent corticosteroid) at dose >10 mg/day
  • Any one of the following laboratory values at screening:

    • levels \< 8.0 g/dL
    • White blood cells (WBC) count \< 2.0 x 10E3/µL
    • count \< 80 x 10E3/µL
    • (ANC) \< 0.8 x 10E3/µL
  • Active viral, bacterial or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent infection or of recurrent bacterial infections with encapsulated organisms
  • History of to any of the study drugs or its or to drugs of similar chemical classes (e.g., mAb of IgG1 class) or to any of the constituents of the study drug formulation (sucrose, L-histidine hydrochloride/ L-histidine, polysorbate 20)
  • History of major organ, hematopoietic stem cell or bone marrow transplant
  • Required regular use of medications known to cause dry mouth/eyes as a regular and major side effect, and which have not been on a stable dose for at least 30 days prior to Screening, or any anticipated change in the treatment regimen during the course of the study
  • Use of topical ocular prescription medications (excluding artificial tears, gels, lubricants) that have not been on a stable dose for at least 90 days prior to randomization, or any anticipated change in the treatment regimen during the course of the study
  • Receipt of live/attenuated vaccine within a 4-week period prior to randomization
  • History of primary or secondary immunodeficiency, including a positive (HIV) test result
  • History of of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer or Sjögren's related lymphoma), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • History of sarcoidosis
  • Any surgical, medical (e.g., uncontrolled hypertension, heart failure or diabetes mellitus), psychiatric or additional physical condition that the Investigator feels may jeopardize the patient in case of participation in this study
  • Chronic infection with (HBV) or (HCV) virus. Positive serology for hepatitis B surface antigen (HBsAg) excludes the subject.

    • HBsAg negative subjects who are hepatitis B core antibody (HBcAb) positive are also excluded unless all of the following criteria are met:

      1. HBV DNA is negative
      2. hepatitis B monitoring is implemented - in these subjects, monthly testing of HBsAg and HBV DNA must be performed while on study treatment and at least every 12 weeks after end of treatment for the entire duration of safety follow-up.
      3. Antiviral prophylaxis must be implemented before the first administration of the study treatment, and continued up to 12 months after the end of study treatment. If antiviral therapy cannot be given or if the patient is not willing to comply with the antiviral treatment requirement, the patient is not eligible for the study.
    • Hepatitis C: patients with positive hepatitis C antibody and HCV-RNA at screening are excluded. Chronic hepatitis C patients who have completed HCV anti-viral treatment must be HCV-RNA negative at least 12 weeks after treatment before randomization to be eligible. Cases of spontaneous HCV clearance should be discussed with sponsor before enrollment.
  • Evidence of active tuberculosis (TB) infection is exclusionary. Patients with previously treated TB and previously treated or newly diagnosed latent TB may be eligible.
  • Pregnant or nursing (lactating) women.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while on study treatment and for 6 months after stopping of investigational medication.
  • Patients with a known history of non-compliance to medication, or who were unable or unwilling to complete PRO questionnaires, or who are unable or unwilling to use the device for collection of PROs.
  • United States (and other countries, if locally required): Sexually active males, unless they agree to use barrier protection during intercourse with a woman of childbearing potential, while taking study treatment. As condom use alone has a reported failure rate exceeding 1% per year, it is recommended that female partners of male study participants use a second method of birth control. Although ianalumab is not teratogenic and/or genotoxic, and not transferred to semen, male contraception is required, as requested by FDA.

Globally, for all sexually active males, contraception should be used in accordance with locally approved prescribing information of concomitant medications administered.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    Arm A

    ianalumab

    Biological: VAY736

  • Placebo comparator
    Arm B

    placebo

    Other: Placebo

Interventions

  • BiologicalVAY736

    ianalumab s.c.

  • OtherPlacebo

    placebo s.c.

06

What researchers measure

Primary outcomes

  1. Change from baseline in EULAR Sjogren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo

    Efficacy (Plan A: US and US reference countries and Plan B: EU, China, other non-US Regions and EU reference countries) Dose response measured by change multi-dimensional disease activity as assessed by the physician. Score range is 0-123. Higher scores on the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states A negative change from baseline indicates improvement in disease status.

    Time frame: 48 weeks

Secondary outcomes

  1. Achieving ESSDAI response at Week 48

    Efficacy (Plan A and B) Dose response measured by change multi-dimensional disease activity as assessed by the physician. Score range is 0-123. Higher scores on the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states A negative change from baseline indicates improvement in disease status.

    Time frame: 48 weeks

  2. Achieving ESSDAI score <5 at Week 48

    Efficacy (Plan A and B) Dose response measured by change multi-dimensional disease activity as assessed by the physician. Score range is 0-123. Higher scores on the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states A negative change from baseline indicates improvement in disease status.

    Time frame: 48 weeks

  3. Achieving ESSDAI response at Week 24

    Efficacy (Plan A and B) Dose response measured by change multi-dimensional disease activity as assessed by the physician. Score range is 0-123. Higher scores on the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states A negative change from baseline indicates improvement in disease status.

    Time frame: 24 weeks

  4. Achieving SSSD response at Week 48

    Efficacy (Plan B) The Sjogrens Syndrome Symptom Diary (SSSD) is questionnaire consists of five (six for females) questions about symptoms of Sjögren's syndrome, each question given a score of 0-10 (0=no symptoms, 10=worst possible symptoms) where patient choose the one response that best describes how severe the symptom was at its worst in the PAST 24 HOURS. It includes six symptom items (eye dryness, mouth dryness, skin dryness, physical fatigue, muscle and/or joint pain, genital dryness), and applies a recall period of 24 hrs. The aim of the SSSD is to establish patient reported endpoints for the treatment of Sjogrens syndrome. Participants will complete the diary daily for 7 days prior to the scheduled dosing.

    Time frame: 48 weeks

  5. Change from baseline in stimulated whole salivary flow rate at Week 48

    Efficacy (Plan A and B)

    Time frame: 48 weeks

  6. Change from baseline in Physician's Global Assessment (PhGA) of disease activity at Week 48

    Efficacy (Plan A and B)

    Time frame: 48 weeks

  7. Change from baseline in Patient's Global Assessment (PaGA) of disease activity at Week 48

    Efficacy (Plan A and B)

    Time frame: 48 weeks

  8. Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score at Week 48

    Efficacy (Plan A and B)

    Time frame: 48 weeks

  9. Achieving EULAR Sjögren Syndrome Patient Reported Index (ESSPRI) response at Week 48

    Efficacy (Plan B)

    Time frame: 48 weeks

Other outcomes

  1. Incidence of Treatment Emergent Adverse Event (TEAEs)/Serious Adverse Events (SAEs) upto the end of the study

    Safety (Plan A and B)

    Time frame: through study completion upto 2 years

  2. Incidence of anti-ianalumab antibodies in serum Anti Drug Antibody (ADA) assay) up to end of study

    Immunogenicity (Plan A and B)

    Time frame: through study completion up to 2 years

  3. Ianalumab concentration in serum during the treatment (example Ctrough) and follow-up (up to end of study)

    Pharmacokinetics (Plan A and B)

    Time frame: through study completion up to 2 years

07

Study locations

77 sites
  • Medvin Clinical Research
    Van Nuys, California 91405, United States
  • West Broward Rheumatology Associates Inc
    Tamarac, Florida 33321, United States
  • Indiana Univ School of Dentistry
    Indianapolis, Indiana 46202, United States
  • Ochsner Health System
    Baton Rouge, Louisiana 70809, United States
  • The John Hopkins Jerome L Greene Sjogren
    Baltimore, Maryland 21224, United States
  • NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • STAT Research Inc
    Dayton, Ohio 45402, United States
  • Altoona Center for Clin Res
    Duncansville, Pennsylvania 16635, United States
  • Precision Comprehensive Research
    Colleyville, Texas 76034, United States
  • Metroplex Clinical Research
    Dallas, Texas 75231, United States
  • Baylor College Of Medicine
    Houston, Texas 77030, United States
  • Houston Rheumatology and Arthrit
    Katy, Texas 77494, United States
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Stockerau, 2000, Austria
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Vitória, Espírito Santo 29055 450, Brazil
  • Novartis Investigative Site
    Juiz de Fora, Minas Gerais 36010 570, Brazil
  • Novartis Investigative Site
    Ribeirão Preto, São Paulo 14048-900, Brazil
  • Novartis Investigative Site
    São Paulo, 01409-902, Brazil
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 7500571, Chile
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 7500710, Chile
  • Novartis Investigative Site
    Guangzhou, Guangdong 510630, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518020, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Baotou, Inner Mongolia 014010, China
  • Novartis Investigative Site
    Hohhot, Inner Mongolia 010050, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Shenyang, Liaoning 110011, China
  • Novartis Investigative Site
    Linyi, Shandong 276000, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030000, China
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
  • Novartis Investigative Site
    Beijing, 100050, China
  • Novartis Investigative Site
    Brno, 638 00, Czechia
  • Novartis Investigative Site
    Prague, 148 00, Czechia
  • Novartis Investigative Site
    Uherské Hradiště, 686 01, Czechia
  • Novartis Investigative Site
    Caen, 14033, France
  • Novartis Investigative Site
    Dijon, 21000, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Marseille, 13005, France
  • Novartis Investigative Site
    Paris, 75010, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Saint-Priest-en-Jarez, 42270, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Erlangen, 91056, Germany
  • Novartis Investigative Site
    Gommern, 39245, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67063, Germany
  • Novartis Investigative Site
    Guatemala City, 01009, Guatemala
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Guatemala City, 01011, Guatemala
  • Novartis Investigative Site
    Quetzaltenango, 9001, Guatemala
  • Novartis Investigative Site
    Vilnius, 08406, Lithuania
  • Novartis Investigative Site
    Guadalajara, Jalisco 44650, Mexico
  • Novartis Investigative Site
    Mexico City, Mexico City 06700, Mexico
  • Novartis Investigative Site
    Wroclaw, Lower Silesian Voivodeship 52-210, Poland
  • Novartis Investigative Site
    Bydgoszcz, 85-168, Poland
  • Novartis Investigative Site
    Krakow, 30-002, Poland
  • Novartis Investigative Site
    Lublin, 20-090, Poland
  • Novartis Investigative Site
    Braga, 4710243, Portugal
  • Novartis Investigative Site
    Guarda, 6301-858, Portugal
  • Novartis Investigative Site
    Lisbon, 1050-034, Portugal
  • Novartis Investigative Site
    Lisbon, 1349-019, Portugal
  • Novartis Investigative Site
    Lisbon, 1649-035, Portugal
  • Novartis Investigative Site
    Singapore, S308433, Singapore
  • Novartis Investigative Site
    Gwangju, 61469, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Badalona, Barcelona 08916, Spain
  • Novartis Investigative Site
    Sabadell, Barcelona 08208, Spain
  • Novartis Investigative Site
    Bilbao, Bizkaia 48013, Spain
  • Novartis Investigative Site
    A Coruña, 15006, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Ankara, Bilkent Cankaya 06800, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Sihhiye-Altindag 06230, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Yenimahalle 06500, Turkey (Türkiye)
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in May 2025, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 27, 2022
StartActual
Jul 28, 2022
Primary completionActual
May 7, 2025
CompletionActual
Jun 2, 2026
Results delay requested
May 6, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05350072
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Jul 28, 2022
Primary completion
May 7, 2025
Completion
Jun 2, 2026
Last update
Jul 7, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion